Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Endocrinol Metab (Seoul). 2024 Jun;39(3):425-444. doi: 10.3803/EnM.2023.1802. Epub 2024 Jun 10.
Thyroid cancer is a common endocrine malignancy with increasing incidence globally. Although most cases can be treated effectively, some cases are more aggressive and have a higher risk of mortality. Inhibiting RET and BRAF kinases has emerged as a potential therapeutic strategy for the treatment of thyroid cancer, particularly in cases of advanced or aggressive disease. However, the development of resistance mechanisms may limit the efficacy of these kinase inhibitors. Therefore, developing precise strategies to target thyroid cancer cell metabolism and overcome resistance is a critical area of research for advancing thyroid cancer treatment. In the field of cancer therapeutics, researchers have explored combinatorial strategies involving dual metabolic inhibition and metabolic inhibitors in combination with targeted therapy, chemotherapy, and immunotherapy to overcome the challenge of metabolic plasticity. This review highlights the need for new therapeutic approaches for thyroid cancer and discusses promising metabolic inhibitors targeting thyroid cancer. It also discusses the challenges posed by metabolic plasticity in the development of effective strategies for targeting cancer cell metabolism and explores the potential advantages of combined metabolic targeting.
甲状腺癌是一种常见的内分泌恶性肿瘤，全球发病率呈上升趋势。尽管大多数病例可以有效治疗，但有些病例侵袭性更强，死亡率更高。抑制 RET 和 BRAF 激酶已成为治疗甲状腺癌的一种潜在治疗策略，特别是在晚期或侵袭性疾病中。然而，耐药机制的发展可能会限制这些激酶抑制剂的疗效。因此，开发针对甲状腺癌细胞代谢并克服耐药性的精确策略是推进甲状腺癌治疗的一个关键研究领域。在癌症治疗领域，研究人员探索了联合治疗策略，包括双重代谢抑制以及代谢抑制剂与靶向治疗、化疗和免疫治疗相结合，以克服代谢可塑性的挑战。本综述强调了甲状腺癌治疗需要新的治疗方法，并讨论了针对甲状腺癌的有前途的代谢抑制剂。它还讨论了代谢可塑性在制定针对癌症细胞代谢的有效策略方面带来的挑战，并探讨了联合代谢靶向的潜在优势。
